Fetal and Neonatal Alloimmune Thrombocytopenia due to Human Platelet Antigen 1 incompatibility research hub

A Phase 2, Multicenter, Open-label Study to Evaluate the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization

This study looks into a new medicine (RLYB212) for pregnant women at risk of a rare condition called FNAIT. It aims to see how the medicine works in their bodies and if it's safe for both mother and baby. FNAIT can cause serious bleeding in newborns.